Leerink Partners analyst Thomas Smith reiterated a Buy rating on Keros Therapeutics (KROS – Research Report) on May 6 and set a price target of $35.00.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Thomas Smith has given his Buy rating due to a combination of factors that highlight the potential growth and strategic direction of Keros Therapeutics. The company is on track to release important topline data from its Phase 2 TROPOS trial for cibotercept in pulmonary arterial hypertension (PAH) this quarter, which could significantly impact its valuation. Despite previous challenges with the trial, including the voluntary halt of high-dose arms due to pericardial effusion events, the management remains optimistic about identifying specific patient characteristics that could mitigate these risks.
Additionally, Keros Therapeutics is actively pursuing strategic alternatives and expects to provide an update soon. The company’s recent Phase 1 data for KER-065 in healthy volunteers showed promising results, with increases in lean muscle mass and improvements in metabolic markers. This positions Keros well for future regulatory engagements and potential trials in Duchenne Muscular Dystrophy (DMD). Overall, the underappreciated value of Keros shares, combined with these developments, supports the Buy rating.
KROS’s price has also changed dramatically for the past six months – from $66.450 to $13.760, which is a -79.29% drop .